profound: olaparib vs enzalutamide or abiraterone for mcrpc with hrr gene alterations
Published 4 years ago • 328 plays • Length 10:21Download video MP4
Download video MP3
Similar videos
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
4:30
profound: olaparib for hrr mcrpc
-
1:15
brcaaway: abiraterone with olaparib in mcrpc with hrr mutations
-
3:05
mcrpc: the importance of genomic profiling
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
6:39
profound: parp inhibitor olaparib compared with new hormonal agents in advanced castration resis...
-
4:21
phase ii results of olaparib and abiraterone for mcrpc
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
1:37
olaparib plus abiraterone for mcrpc: are biomarkers necessary?
-
3:41
olaparib plus abiraterone could be a new first-line treatment option for mcrpc | fred saad
-
5:15
rucaparib and olaparib: two new treatments approved for advanced prostate cancer | pcri
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
1:40
dr. maughan discusses abiraterone plus olaparib in mcrpc
-
9:15
fda approval of lynparza® in us for hrr gene-mutated mcrpc
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
16:07
profound trial shows increased rpfs in mcrpc patients with brca1, brca2, and atm mutations
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc